Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 603 All time
- Disclosed funding
- $28.7B 480 disclosed amounts
- Median round
- $17M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| A Builds AI-ready lab automation platforms for life sciences | $45M | Series CSeries C+ | Biotech, Industrial tech | United Kingdom | Investors | |
| P PrenosisCompany profile Develops integrated diagnostics and therapeutics for critical care conditions Develops integrated diagnostics and therapeutics for critical care conditions | $20M | Series A | Biotech | United States | Investors | |
| ET Elysium TherapeuticsCompany profile Develops treatments to prevent and reverse overdoses caused by synthetic opioids Develops treatments to prevent and reverse overdoses caused by synthetic opioids | $7.5M | SAFEUndisclosed | Biotech | United States | Investors Undisclosed | |
| HA Heritable AgricultureCompany profile Develops AI-driven crop improvement solutions for climate-resilient crops Develops AI-driven crop improvement solutions for climate-resilient crops | $5M | GrantUndisclosed | Biotech, Agritech | United States | Investors | |
CellaresCompany profile Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network. Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network. | $257M | Series DSeries C+ | Biotech | United States | Investors | |
| SB Stellular BioCompany profile Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases | Undisclosed | Series A | Biotech | United States | Investors | |
| TB Develops precision immunoregulatory medicines based on tissue Treg biology | $50M | Undisclosed | Biotech | United States | Investors | |
| N NavidenceCompany profile Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research | Undisclosed | Seed | Biotech, Healthtech | United States | Investors | |
AntheiaCompany profile Antheia manufactures pharmaceutical ingredients through biosynthesis, using controlled fermentation to supply drugmakers with key starting materials and active ingredients. Antheia manufactures pharmaceutical ingredients through biosynthesis, using controlled fermentation to supply drugmakers with key starting materials and active ingredients. | $24M | Series C second closeSeries C+ | Biotech | United States | Investors | |
Provides data analysis for quality and regulatory intelligence. | Undisclosed | Pre-SeedPre-seed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Delix Therapeutics, Alethio Therapeutics, Estuary Biotherapeutics
27rounds6led - 2Eli Lilly and Company
Oyster Therapeutics, BigHat Biosciences, Circle Pharma, Inc.
16rounds0led - 3Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
16rounds1led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
16rounds1led - 5OrbiMed
Dren Bio, Star Therapeutics, Leal Therapeutics
12rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.